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Abstract
Background: Four antigenically distinct serotypes (1–4) of dengue viruses (DENVs) cause dengue disease. Antibodies
to any one DENV serotype have the potential to predispose an individual to more severe disease upon infection with a
different DENV serotype. A dengue vaccine must elicit homotypic neutralizing antibodies to all four DENV serotypes to
avoid the risk of such antibody-dependent enhancement in the vaccine recipient. This is a formidable challenge as
evident from the lack of protective efficacy against DENV-2 by a tetravalent live attenuated dengue vaccine that has
completed phase III trials recently. These trial data underscore the need to explore non-replicating subunit vaccine
alternatives. Recently, using the methylotrophic yeast Pichia pastoris, we showed that DENV-2 and DENV-3 envelope (E)
glycoproteins, expressed in absence of prM, implicated in causing severe dengue disease, self-assemble into virus-like
particles (VLPs), which elicit predominantly virus-neutralizing antibodies and confer significant protection against lethal
DENV challenge in an animal model. The current study extends this work to a third DENV serotype.
Results: We cloned and expressed DENV-1 E antigen in P. pastoris, and purified it to near homogeneity. Recombinant
DENV-1 E underwent post-translational processing, namely, signal peptide cleavage and glycosylation. Purified DENV-1
E self-assembled into stable VLPs, based on electron microscopy and dynamic light scattering analysis. Epitope
mapping with monoclonal antibodies revealed that the VLPs retained the overall antigenic integrity of the virion
particles despite the absence of prM. Subtle changes accompanied the efficient display of E domain III (EDIII), which
contains type-specific neutralizing epitopes. These VLPs were immunogenic, eliciting predominantly homotypic
EDIII-directed DENV-1-specific neutralizing antibodies.
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Conclusions: This work demonstrates the inherent potential of P. pastoris-expressed DENV-1 E glycoprotein to
self-assemble into VLPs eliciting predominantly homotypic neutralizing antibodies. This work justifies an investigation
of the last remaining serotype, namely, DENV-4, to assess if it also shares the desirable vaccine potential manifested by
the remaining three DENV serotypes. Such efforts could make it possible to envisage the development of a tetravalent
dengue vaccine based on VLPs of P. pastoris-expressed E glycoproteins of the four DENV serotypes.
Keywords: Virus-like particles, Dengue virus, Envelope glycoprotein, Envelope domain III, Pichia pastoris, Neutralizing
antibody, Antibody dependent enhancement
Background
Dengue disease is a global public health threat caused by
four distinct serotypes of dengue viruses (DENV-1, −2, −3
and −4) spread primarily by Aedes aegypti mosquito [1].
According to a report in the year 2013, the number of an-
nual global dengue infections was estimated to be ~400
million, with ~96 million clinically apparent infections [2].
DENV is a positive sense RNA virus with ~11 kilo base
(kb) genome, which encodes three structural and seven
non-structural proteins [3]. Dengue disease can vary from
mild dengue fever to severe, life-threatening syndromes,
dengue hemorrhagic fever and dengue shock syndrome
[1, 4, 5]. DENV infection, which results in lifelong homo-
typic immunity, affords only transient heterotypic immun-
ity [6]. In fact, heterotypic antibodies are implicated in
promoting DENV uptake during a secondary infection
with a different serotype, through Fc receptor pathway
and contributing to increased viral load, leading to more
severe disease [1, 7]. To preclude the possibility of such
antibody-mediated enhancement (ADE) of dengue dis-
ease, it is believed that a safe dengue vaccine must be
‘tetravalent’, affording simultaneous type-specific (homoty-
pic) protection against each of the four DENV serotypes.
This requirement poses a major hurdle to dengue vaccine
development [8]. Many live attenuated vaccine candidates
are in clinical development. Of these, Sanofi’s Chimeric
Yellow Fever Dengue-Tetravalent Dengue Vaccine (CYD-
TDV) has recently completed Phase III trials [9, 10] and is
currently being introduced in some dengue-endemic
countries [11]. However, this vaccine candidate has cer-
tain limitations. It needs to be administered in 3 doses
over a one year period. CYD-TDV is not as effective in
dengue-naïve individuals, as in those with a history of
prior dengue exposure. Its efficacy against DENV-2 is
very low, despite its apparent capacity to induce sero-
type 2-specific neutralizing antibodies [9, 10]. Efforts to
understand this, using a mouse model of ADE, strongly
suggest that while homotypic neutralizing antibodies do
not cause ADE, heterotypic neutralizing antibodies do,
at certain concentrations [12]. This underscores the re-
quirement for a dengue vaccine to elicit homotypic
neutralizing antibodies to each of the four prevalent
DENV serotypes to be both safe and efficacious.
Using a non-replicating subunit vaccine approach, we
showed recently that it is possible to elicit predomin-
antly homotypic neutralizing antibody titers using P.
pastoris-expressed envelope (E) glycoproteins of DENV-
2 and DENV-3 in mice [13, 14]. The DENV-E protein is
the major surface exposed glycoprotein of about ~500
amino acid (aa) residues, which is organized into three
discrete domains, EDI, EDII and EDIII [15]. Of these,
EDIII is critical from a vaccine perspective, as it is not
only involved in host receptor recognition and virus
entry into susceptible cells, but also in the induction of
potent type-specific virus neutralizing antibodies [16, 17].
Interestingly, our work showed that the N-terminal 80 %
of the E glycoprotein (ectodomain) of DENV-2 [13] and
DENV-3 [14], which encompasses EDIII, produced
using P. pastoris assembled into discrete virus-like par-
ticles (VLPs). These VLPs served as efficient display
platforms for EDIII and elicited potent, homotypic
virus-neutralizing antibodies [13, 14], capable of con-
ferring significant protection against live virus chal-
lenge in an animal model [13]. Unlike dengue virion
particles which contain E along with another structural
protein, prM, implicated in the induction of ADE-
mediating antibodies [18, 19], these VLPs contain only
the E glycoprotein. Thus, the P. pastoris-derived DENV
E VLPs, lacking the ADE-associated prM protein, offer
a significant safety advantage. This has provided us the
rationale to explore the feasibility of developing DENV
E VLPs corresponding to the remaining two serotypes
as well, so that we may eventually develop a tetravalent
DENV E VLP-based vaccine candidate.
In this paper, we specifically focus on expressing and
characterizing DENV-1 E glycoprotein using P. pastoris
to address the following specific questions: (i) Will
DENV-1 E glycoprotein, expressed in P. pastoris, also
possess VLP-forming potential? (ii) Would these VLPs
preserve the antigenic integrity of the critical virus-
neutralizing epitopes? (iii) Would the VLPs be im-
munogenic, and if so, would the antibodies elicited be
homotypic? The work described in this paper demon-
strates the feasibility of creating P. pastoris-expressed
DENV-1 E-based VLPs that are capable of eliciting
EDIII-directed type-specific neutralizing antibodies and
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moves a step closer to developing a tetravalent dengue
VLP vaccine candidate.
Results
Recombinant DENV-1 E undergoes proper processing and
glycosylation in P. pastoris and self- assembles into stable
VLPs
A synthetic DENV-1 E gene encoding the C-terminal 34
aa residues of prM as a signal peptide, followed by the
N-terminal 395 aa ectodomain of the E glycoprotein of
DENV-1, pentaglycyl linker and a stretch of 6 histidine
residues was cloned into pPICZA vector and expressed in
KM71H strain of P. pastoris (Additional file 1: Figure S1).
The expressed recombinant DENV-1 E protein which was
associated with the membrane fractions was affinity-
purified under denaturing conditions (Additional file 1:
Figure S2). As observed earlier for the E proteins of
DENV-2 [13] and DENV-3 [14], the DENV-1 E protein
was also processed properly by P. pastoris, based on N-
terminal sequence analysis, which showed that the
prM-derived signal peptide had been removed. Electron
microscopic (EM) and dynamic light scattering (DLS)
analyses revealed the purified DENV-1 E protein to be
assembled into ~38 nm VLPs (Fig. 1). This, taken to-
gether with our previous observations, confirms the in-
herent ability of P. pastoris-DENV E ectodomain to
self-assemble into VLPs in the absence of prM protein.
Further, we observed that the VLP nature was pre-
served upon storage at 37 °C for 14 days (Fig. 2). In
fact, DLS analysis of stored VLPs showed them to be
comparatively larger, suggesting that these VLPs mature
further, as observed earlier for other viral antigen-
derived VLPs [13, 20]. N-linked oligosaccharide profil-
ing by MALDI-TOF mass spectroscopy revealed the
presence of mannosylated population of glycans linked
to DENV-1 E protein. These glycans consisted of a
common pentasaccharide core (Man3GlcNAc2) with 4–
8 additional mannose residues (Fig. 3). The precise sig-
nificance of such P. pastoris-mediated glycosylation of
the E glycoprotein, from a vaccine perspective, is not
clear. Presumably, it may have a role in antigen uptake
and processing [21].
DENV-1 E VLPs display key viral epitopes on their surface
The DENV-1 E VLPs were antigenically characterized
with a panel of murine and human mAbs [17, 22–28]
specific to various surface exposed epitopes of the virus
(Table 1). Of these mAbs, those that bind to the lateral
ridge (LR) of EDIII are notable. The EDIII LR epitope,
mapping to aa residues 301, 302, 329, 330 and 386,
elicits potent virus-neutralizing antibodies [16, 17].
Using an indirect ELISA format described recently [14],
we found that the DENV-1 E VLPs reacted strongly with
DENV-1-specific mAb E103. This mAb which binds to
aa residues on BC and DE loop of EDIII LR epitope, is
documented to neutralize multiple DENV-1 genotypes,
namely, TVP-2130, 16007, TVP-5175, West Pac-74 and
3146- SL [17]. Consistent with its type-specificity, mAb
E103 does not recognize DENV-2 E and DENV-3 E
VLPs. This demonstrates that the DENV-1 E VLPs re-
tain the type-specific EDIII-LR epitope of DENV-1 and
display it efficiently to mAb E103. The EDIII-LR epitope
displayed on the DENV-1 E VLP surface largely retains
its serotype 1-specific antigenic character is corroborated
by the lack of significant ELISA reactivity towards
DENV-2 mAb 3H5 [22], DENV-3 mAb 8A1 [23] and
DENV-4 mAb E88 [24]. Apart from the LR epitope, the
VLPs also displayed other EDIII-specific epitopes effi-
ciently, based on the ELISA reactivity, manifested to-
wards DENV-1 mAbs E24, E29 and E37 [17]. Consistent
with these observations several cross-reactive murine
and human mAbs specific to EDIII, within (mAb E77)
and outside the LR (mAbs 12C1, h-2 J20), also recog-
nized the DENV-1 E VLPs efficiently. Additionally, the
VLPs also displayed EDI/II epitopes, indicated by their
reactivity towards mAb E17 [25], and fusion-loop epi-
topes, based on their recognition by mAbs h-1 M7 [27]
and 4G2 [22]. Consistent with the design of DENV-1 E
antigen, we did not detect any ELISA reactivity of the
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Fig. 1 Investigation of VLP formation by purified DENV-1 E protein. a EM analysis of DENV-1 E VLPs by negative staining with 1 % uranyl acetate.
b DLS analysis of particle size distribution by volume
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DENV-1 E VLPs towards prM-specific mAb 2 K2 [28].
Collectively, these data show that the DENV-1 E VLPs
largely retain the epitope architecture of the virion. Not-
ably, they display EDIII and its type-specific epitopes
quite efficiently on their surface.
DENV-1 E VLPs elicit EDIII-directed type-specific virus-
neutralizing antibodies in mice
The observation that DENV-1 E VLPs retain many epi-
topes recognized by neutralizing mAbs suggested that
they must be immunogenic and be capable of anti-
DENV-1 immune response. To ascertain this, BALB/c
mice were immunized with DENV-1 E VLPs on days 0,
30 and 90, as reported earlier [13, 14]. Mice were bled
on days 37 and 100 and sera were evaluated for presence
of antibodies by indirect ELISA using purified DENV-1
E as the coating antigen (Fig. 4). The ELISA reactivity of
day 100 serum on DENV-1 E VLPs was significantly
higher than day 37 serum (Fig. 4a), indicating that day
90 dose boosted the immune response. Next, we evalu-
ated the extent of cross-reactivity of anti-DENV-1 E
antiserum towards DENV-2 E [13] and DENV-3 E [14]
VLPs described earlier. We observed that antibodies
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Fig. 2 VLPs stability study. DLS analysis of DENV-1 E VLP size distribution by volume after incubating them for 2 weeks at (a) 4 °C or (b) 37 °C
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Fig. 3 MALDI-TOF-MS analysis of N-linked Oligosaccharides of
P. pastoris-expressed DENV-1 E protein. a Tabular representation of
molecular weights of sugars attached to DENV-1 E protein with
their respective structures, number of mannose residues and their
percent area (% area). The % area corresponds to the relative proportion
of the oligosaccharide out of total oligosaccharide populations.
b Graphical representation of peaks corresponding to different
molecular weight sugars with their respective intensities on y-axis
and corresponding mass/charge (m/z) ratios on x-axis
Table 1 Analysis of antigenic integrity of DENV-1 E VLPsa
Type-specific murine mAbs
mAbb Epitope
Specificity
Absorbance, 450 nm
DENV-3 E DENV-2 E DENV-1E HBsAg
DENV1 E24 EDIII 0.03 0.02 1.23 0.03
DENV1 E29 EDIII 0.09 0.03 1.87 0.03
DENV1 E37 EDIII 0.03 0.02 0.71 0.04
DENV1 E103 EDIII, LR 0.06 0.06 3.48 0.02
DENV-2 3H5 EDIII, LR 0.06 3.46 0.14 0.06
DENV-3 8A1 EDIII, LR 1.35 0.02 0.08 0.03
DENV-4 E88 EDIII, LR 0.03 0.07 0.05 0.05
Cross-reactive murine & human mAbs
mAb Epitope
Specificity
Absorbance, 450 nm
DENV-3 E DENV-2 E DENV-1E HBsAg
E17c EDI/II 3.45 3.47 3.42 0.07
4G2d Fusion loop 0.83 0.20 0.23 0.06
12C1d EDIII, not LR 3.72 3.86 3.76 0.02
E77Com EDIII, AS, LR 2.41 1.21 3.50 0.04
h-1M7d Fusion loop 2.48 3.03 2.97 0.01
h-2 J20 EDIII 3.58 3.46 3.67 0.06
h-2 K2 prM 0.04 0.03 0.03 0.06
aDetermined by indirect ELISA using P. pastoris-produced purified DENV E VLPs
as coating antigens. For comparison, corresponding data for DENV-2 E and
DENV-3 E VLPs [14] are shown
bThe type-specific mAbs used are described in literature: DENV-1 mAbs E24,
E29, E37 & E103 [17]; DENV-2 mAb 3H5 [22]; DENV-3 mAb 8A1 [23]; DENV-4
mAb E88 [24] . Cross-reactive mAbs: E17 [25]; 4G2 [22]; 12C1 [23]; h-1 M7 [27];
h-2 J20 [26] & h-2 K2 [28]; All mAb are murine, except the last 3 which are
human (prefixed ‘h’)
cSub-complex-specific mAbs; E17 recognizes EDI/II of DENV-1 and DENV-3
dComplex-specific mAbs; 4G2 and h-1 M7 bind the fusion loop of all four DENV
Es; 12C1 binds recombinant EDIII (outside the LR epitope) of all four
DENV serotypes
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elicited by DENV-1 E do recognize and bind to DENV-2
E and DENV-3 E (Fig. 4b). However, the heterotypic
ELISA reactivity was noticeably lower than the homoty-
pic ELISA reactivity. The heterotypic ELISA reactivity
is presumably due to the presence of cross-reactive
(EDI/II and FL) epitopes on the VLPs observed in this
study (Table 1). This pattern of cross-reactivity was
mirrored in indirect ELISAs performed using recom-
binant EDIII proteins of the four serotypes (Fig. 4c) or
the intact viruses themselves (Fig. 4d) as the coating
antigens. The observation that anti-DENV-1 E VLP-
antibodies recognize DENV-1 (Fig. 4d) was corrobo-
rated by IFA, as depicted in Fig. 4e. This experiment
showed that antibodies elicited by DENV-1 E VLPs rec-
ognized and bound to DENV-1 in infected BHK-21
cells efficiently (Fig. 4e, panel iii). Next, we assessed the
virus-neutralizing efficacy of these DENV-1 E VLP-
induced antibodies using a FACS based neutralization
assay [13, 14]. Testing each one of the four DENVs in
this assay, we found that the anti-DENV-1 E VLP
antiserum possessed FNT50 titre of 179 against DENV-
1, with no discernible neutralizing titers towards any of
the remaining three DENV serotypes (Fig. 5). This ob-
servation of homotypic neutralizing activity is essen-
tially consistent with our observations with DENV-2 E
and DENV-3 E VLPs reported earlier [13, 14]. As these
studies had revealed that the homotypic neutralizing
antibody titers are predominantly EDIII-focused, we
sought to ascertain this in case of DENV-1 E-induced
antibodies as well. Thus, as done earlier (14), a deple-
tion assay was performed wherein DENV-1 EDIII-specific
antibodies were removed from anti-DENV-1 E VLP im-
mune serum by incubating it with a maltose-binding pro-
tein (MBP) fusion of DENV-1-derived recombinant EDIII
immobilized on amylose resin. As expected, following this
depletion the anti-DENV-1 E VLP antiserum manifested
very little reactivity in an ELISA using EDIII as the coating
antigen (Fig. 6a). The question we addressed at this point
was, what is the effect of depleting anti-EDIII antibodies
on ELISA reactivity towards the E glycoprotein? A similar
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Fig. 4 Characterization of antibodies generated by DENV-1 E VLPs. Pooled sera from mice immunized with DENV-1 E VLPs, collected on day 37
(dashed line) and day 100 (solid line) were analysed in indirect ELISA format using DENV-1 E VLPs as the coating antigen (a). Pooled day 100
immune serum was evaluated for reactivity using DENV-E VLPs (b), recombinant EDIIIs (c), and intact DENVs (d) taken as coating antigens,
corresponding to serotypes 1 (red curve), 2 (green curve), 3 (blue curve) and 4 (black curve). Grey lines (in all panels) represented serum from
PBS-immunized BALB/c mice. e Indirect immunofluorescence analysis of DENV-1 infected BHK-21 cells using (i) PBS-immunized serum (ii) 4G2
mAb (iii) anti-DENV-1 E VLP antiserum taken as the source of primary antibodies. Anti-mouse IgG-FITC conjugate was used to visualize
bound antibodies
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ELISA, performed using recombinant DENV E VLPs as
the capture antigen revealed that EDIII antibody depletion
did not affect DENV-1 E specific antibody titers (Fig. 6b).
Having verified that the anti-DENV-1 E antiserum had
been specifically depleted of EDIII-directed antibodies
alone, we next determined residual virus-neutralizing anti-
body titers in it (Fig. 6c). This experiment revealed signifi-
cant reduction in DENV-1 virus-specific FNT50 titer,
suggesting that majority of DENV-1 E neutralizing im-
mune response is mediated by EDIII-directed antibodies.
Discussion
Dengue has recently been recognized as one of the fast-
est spreading vector-borne diseases [29]. Since, a pre-
ventive dengue vaccine has been an unmet need for very
long has spurred the introduction of a live attenuated
vaccine (CYD-TDV) recently in a couple of dengue-
endemic countries, despite sub-optimal efficacy in phase
III clinical trials [9, 10]. Attempts to understand the
basis of lack of vaccine efficacy, have revealed that
neutralizing antibody titers elicited by CYD-TDV are
directed predominantly towards one serotype [30], pre-
sumably stemming from viral interference [31–33].
This taken in the context of another recent study,
which demonstrated that neutralizing antibodies need
to be homotypic to preclude the possibility of ADE
[12], strongly suggests that it is important for a safe
and effective dengue vaccine to elicit type-specific neu-
tralizing antibodies to each of the four prevalent
DENV serotypes. This situation warrants a continued
search for alternate non-replicating vaccine candidates
that may hopefully eliminate interference and the asso-
ciated potential safety concerns [34].
Our recent work has shown that in the context of den-
gue, VLPs offer such an alternate option. These VLPs are
spherical, non-replicative, lack viral genomic RNA, and
are highly immunogenic. We reported earlier that the E
glycoproteins of DENV-2 and DENV-3, when expressed
in P. pastoris, in the absence of the companion struc-
tural protein, prM, assemble into discrete VLPs [13, 14].
Several attributes of these VLPs are noteworthy from the
perspective of a dengue vaccine candidate. First is the
observation that prM, a minor structural protein neces-
sary for virion maturation which is documented to elicit
antibodies implicated in ADE [18, 19], is not required
for VLP formation. Second, these VLPs were shown to
preserve the neutralizing epitopes of the cognate DENV
serotype. Interestingly, these VLPs displayed EDIII effi-
ciently. This is significant as EDIII is implicated in host
receptor recognition and contains multiple type-specific
neutralizing epitopes [16, 17]. Third, though these VLPs
elicited antibodies against all the DENV serotypes, they
neutralized only DENV-1, mediated by anti-EDIII anti-
bodies. This is of significance as only cross-reactive
virus-neutralizing antibodies appear to be associated
with ADE [12]. Fourth, in an animal challenge model,
DENV-2 E VLPs afforded statistically significant protec-
tion. Collectively, these findings underlie our efforts to
develop a tetravalent VLP vaccine candidate based on P.
pastoris-expressed DENV E glycoproteins. Towards this
objective, we have extended our VLP vaccine work to a
third DENV serotype, namely, DENV-1, in this paper.
The design of the DENV-1 E antigen gene was exactly
similar to that of DENV-2 and DENV-3 E antigens de-
scribed previously [13, 14]. Moreover, a multiple se-
quence alignment of the four DENV-E aa sequences (of
the specific genotypes of the four serotypes) revealed
60–80 % similarity (Additional file 1: Figure S3), which
is in compliance with the reports in literature [35]. The
DENV-1 E antigen was provided with an N-terminal
DENV-1 prM-derived signal peptide and a C-terminal
6x His tag and expressed in P. pastoris by methanol in-
duction. As reported in the earlier studies, the DENV-
1 E protein was processed similarly by P. pastoris, in
that the prM peptide was cleaved off and the mature
protein glycosylated. Consistent with the behavior of
DENV-2 E and DENV-3 E proteins, the DENV-1 E
protein also self-assembled into VLPs, during down-
stream processing, as evidenced by EM and DLS
in
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Log (1/sera dilution)
Sera DENV-1 DENV-2 DENV-3 DENV-4
DENV-1E 179 ± 44 <20 <20 <20
Fig. 5 Determination of virus neutralization potency of antibodies
induced by DENV-1 E VLPs. Immune sera were serially diluted two-
fold and pre-incubated separately with DENV-1 (red curve), DENV-2
(green curve), DENV-3 (blue curve) and DENV-4 (black curve). The
antibody-virus complexes were allowed to infect Vero cells and
neutralizing antibody titers (FNT50) were determined by using FACS
analysis. The Y and X axes of the graph represent % infected cells
and log of reciprocal of sera dilution, respectively. The dotted
horizontal line in the graph represents 50 % infection. The table on
top of the panel lists the FNT50 titers of DENV-1 E antiserum against
all the four serotypes
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analyses. These VLPs were stable and appeared to ma-
ture to a greater degree of size homogeneity during
storage. Probing the surface of these VLPs using sev-
eral different type-specific and cross-reactive human
and murine mAbs demonstrated that several of the
epitopes that exist on the DENV-1 virion surface are
present on the DENV-1 E VLPs as well. Of note was
the observation that EDIII was displayed on the VLP
surface with its LR epitope, critical for the induction of
type-specific neutralizing antibodies, intact and freely
accessible. Consistent with this, we found that the
DENV-1 E VLPs elicited homotypic neutralizing anti-
bodies. EDIII antibodies elicited by these VLPs were
almost exclusively responsible for neutralizing DENV-
1, as evident from abrogation of neutralizing antibody
titer in immune sera following antibody depletion
using immobilized DENV-1 EDIII antigen. Like the
antibodies induced by DENV-3 E [14], antibodies in-
duced by DENV-1 E VLPs also did not cause hetero-
typic enhancement of DENV infection at 1:20 sera
dilution (data not shown). This underscores the utility
of eliciting serotype-specific neutralizing antibodies to
preclude heterotypic ADE. The data thus far on P.
pastoris-produced DENV-1 E VLPs essentially mirror
our earlier findings with DENV-2 and DENV-3 E
VLPs and provide the rationale for extending this
work to the E glycoprotein of the last remaining sero-
type, DENV-4.
DENV-1E 
antiserum
FNT50
DENV-1 DENV-2 DENV-3 DENV-4
Undepleted (a) 177 ± 26 <20 <20 <20
MBP-Depleted (b) 161 ± 58 <20 <20 <20
EDIII-1 Depleted (c) 23 ± 15 <20 <20 <20
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Fig. 6 Analysis of the role of anti-EDIII antibodies in virus neutralization: DENV-1 E VLP antiserum was used without prior depletion (a) or
treated as follows. It was incubated with immobilized MBP (b) or immobilized MBP-EDIII-1 (c) matrix. Residual antibody titers in these three
DENV-1 E VLP antiserum treatment groups (a, b and c), were analyzed in indirect ELISA using purified recombinant MBP-EDIII-1, −2, −3, −4
protein (panel a) or DENV-1, −2, −3 E VLPs (panel b). Residual neutralizing antibody titers (FNT50) in the same three sera groups were
estimated using the FACS assay (Panel c)
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Conclusion
We have evaluated the potential of P. pastoris-expressed
DENV-1 E glycoprotein-based VLPs as a potential vac-
cine candidate. We show that these DENV-1 E VLPs gen-
erate predominantly EDIII-directed, DENV-1 serotype
specific, neutralizing immune antibody responses. The
complete absence of prM would be an in-built safety ad-
vantage. Multimeric presentation of antigenic epitopes
with predominance of EDIII determinants on DENV-1 E
VLPs may overcome the problem of low immunogenicity
associated with monomeric subunit based vaccine candi-
dates. Stability of VLPs at higher temperature would help
in reducing the challenges faced during vaccine storage
and administration. The P. pastoris-expressed E glycopro-
teins of three DENV serotypes so far studied manifest
several attributes, desirable from a vaccine standpoint,
namely, the capacity to: (i) form immunogenic VLPs,
(ii) efficiently display EDIII that contains type-specific
neutralizing epitopes, and (iii) induce homotypic neu-
tralizing antibody titers. This, coupled to the high
expression potential of the P. pastoris host system
strongly suggests that extension of this work to the last
remaining serotype, DENV-4, may set the stage for de-
veloping a safe, effective and inexpensive VLP dengue
vaccine candidate.
Methods
DENV-1 E gene, expression plasmid, cell line, virus and
other reagents
DENV-1 E gene (~1.3 kb: Genbank accession no:
JX292264) codon-optimized for expression in P. pastoris
system was custom synthesized by GeneScript, New
Jersey, USA. E.coli strain DH5α, P. pastoris strain
KM71H and expression plasmid pPICZA were procured
from Invitrogen Life Technologies, Carlsbad, USA. Vero
and BHK-21 cell lines were purchased from American
Type Cell Culture (ATCC), Virginia, USA. WHO refer-
ence viral strains DENV-1 (WP 74), DENV-2 (S16803),
DENV-3 (CH53489), DENV-4 (TVP-360); E. coli clones
expressing MBP (Maltose Binding Protein) and MBP-
EDIII-1 (EDIII domain of DENV-1 fused with MBP) fu-
sion proteins were received from Dr. Aravinda de Silva,
University of North Carolina (UNC), USA. All mAbs
used in this study were the same as before [13, 14]. Con-
canavalin A (Con A) peroxidase conjugate was purchased
from Sigma-Aldrich. Goat anti-mouse and anti-human
IgG monoclonal antibody-HRPO conjugates and anti-
mouse fluorescein isothiocyanate (FITC) conjugate were
procured from Life Technologies, USA and Merck,
Germany, respectively. Ni-NTA resin was procured from
Qiagen, Hilden, Germany. High binding, polystyrene
ELISA plates were purchased from Corning Incorporated,
USA. N-linked oligosaccharide profiling was performed at
GlycoSolutions Corp., Marlborough, USA.
DENV-1 E gene cloning, expression, purification and
characterization
DENV-1 E gene was cloned at EcoRI and NotI site of
pPICZA expression plasmid. The resultant plasmid
was linearized with Sac I, electroporated into P. pas-
toris strain KM71H and expressed under the control
of AOX1 promoter as done previously for DENV-2 E
[13] and DENV-3 E [14]. Transformants were selected
on zeocin plates and induced with 1.5 % methanol
every 24 h for 72 h. DENV-1 E was purified from in-
duced P. pastoris cells using Ni-NTA chromatography
under denaturing conditions as described previously
[13]. Purified protein was analyzed on Coomassie gel
and Western blot using anti-EDIII mAbs. The identity
and similarities between the amino acid sequences of
DENV-1 (West Pac-74), DENV-2 (New Guinea C),
DENV-3 (H87) and DENV-4 (Dominica) derived re-
combinant E genes with GenBank accession number
JX292264, JX292265, JX292266, JX292267 respectively
was determined by multiple sequence alignment using
Clustal W tool. Further, DENV-1 E protein was evalu-
ated for assembly into VLPs by EM and DLS studies
[14]. Briefly, EM studies were performed by coating
the purified and dialyzed DENV-1 E (at 5–10 ug/ml)
on carbon-formvar grid, followed by negative staining
with 1 % uranyl acetate, which were examined under
electron microscope. Malvern Zetasizer NanoZ was
used to assess the particle size and distribution of
purified and dialysed DENV-1 E VLPs by dynamic
light scattering. The stability of VLPs after incubation
at 37 °C for 14 days was also evaluated by DLS stud-
ies as described before [14]. Further, the protein was
characterized by MALDI-TOF-Mass spectroscopy to
determine the structure of N-linked glycan attached
to protein. The integrity of conformational epitopes
of DENV-1 E protein was evaluated using a panel of
murine and human mAbs by indirect ELISA as re-
ported previously [14]. Further, the reactivity of anti-
bodies in the DENV-1 E VLP immunized mice sera
was evaluated by indirect ELISA and IFA as reported
previously [13, 14]. BALB/c mice (n = 6) were immu-
nized with 20 μg of DENV-1 E VLP on day 0 and
subsequently boosted on days 30 and 90. Mice were
bled on days 37 and 100 for seroanalysis. The
neutralization efficacy of DENV-1 E sera was evalu-
ated against all the four DENV serotypes on Vero cell
line by FACS based neutralization assay as described
before [13, 14]. Further, the proportion of EDIII-
directed neutralizing antibody titers in DENV-1 E
serum was evaluated by pre-incubating it with amyl-
ose resin coated with MBP-fused in-frame to DENV-1
EDIII, prior to use in FACS based DENV
neutralization assay [14]. FACS data were analysed
using FlowJo software.
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